Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (262)	11/14/2001 5:57:05 AM
From: Icebrg	Read Replies (1) \| Respond to of 1022

Nigel I am not so sure their intention is to start licensing this technology to other parties. At least not just yet. This deal looks to me more like the purchase last year of IntraImmune Therapies. I.e. the acquisition of a complementary technology, which will extend the use of MABs beyond "simple" naked antibodies. To a certain extent their license agreement with ImmunoGen does also fit nicely into such a strategy. Coming back to the ABGX/MEDX situation. Perhaps we are seeing two different approaches here. While Medarex are very busy signing up new collaborators for their present generation of MAB-generating techniques, ABGX are already trying to find new ways of extending the use of MABs, beyond the present frontiers. Interesting. Ice